Introduction
Background DVT refers to the formation of blood clots in ≥1 deep veins, usually of the lower or upper extremities. PTS, the most common long-term complication of DVT, occurs in a limb previously affected by DVT. PTS, sometimes referred to as postphlebitic syndrome or secondary venous stasis syndrome, is considered a syndrome because it manifests as a spectrum of symptoms and signs of chronic venous insufficiency, which vary from patient to patient. 1 These can range from minor leg swelling at the end of the day to severe complications such as chronic debilitating lower-limb pain, intractable edema, and leg ulceration, 2 which may require intensive nursing and medical care. PTS increases healthcare costs and reduces quality of life (QoL). 3, 4 The purposes of this scientific statement are to provide current best practice guidelines pertaining to PTS and to serve as an additional resource to healthcare professionals who manage patients with DVT and PTS.
Schulman et al 11 have shown that the probability of developing a venous ulcer over 10 years after DVT was almost 5%. It is projected that the number of adults in the United States with venous thromboembolism (of which DVT is the predominant form) will double from 0.95 million in 2006 to 1.82 million in 2050 14 ; therefore, improved prevention and treatment of DVT are critical in decreasing the incidence of PTS.
Impact on Healthcare Costs and QoL
PTS adversely affects QoL and reduces productivity, 3 leading to substantial burden to patients and the healthcare system. 4, 15, 16 In a Canadian study that assessed the economic consequences of DVT over a 2-year period, the total per-patient cost of PTS Table 1 
. Classification of Recommendations and Levels of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important key clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
was Canadian $4527, a cost that was almost 50% higher than for patients with DVT without PTS. 4 This cost increase was largely attributable to greater use of healthcare visits and prescription medications. The average annual cost of PTS treatment in the United States was estimated at ≈$7000 per patient per year. 15 Caprini et al 17 The high cost of treating venous ulcers is due largely to surgery, lost workdays, and loss of employment. It is estimated that 2 million workdays are lost annually in the United States as a result of leg ulcers. 18 In the assessment of burden of illness for chronic conditions such as PTS, QoL is an important consideration. Ideally, both generic QoL (ie, overall health state) and disease-specific QoL should be assessed. Studies have shown that compared with DVT patients without PTS, patients with PTS have poorer venous disease-specific QoL, 3, [19] [20] [21] [22] and scores worsen significantly with increasing severity of PTS. 19 It is notable that generic physical QoL for patients with PTS is worse than that for people with chronic diseases such as osteoarthritis, angina, and chronic lung disease. 3 
Clinical Manifestations and Pathophysiology Characteristic Symptoms and Signs of PTS
PTS, a form of secondary venous insufficiency, is characterized by a range of symptoms and signs ( Table 2) . Typical symptoms of lower-extremity PTS include pain, swelling, heaviness, fatigue, itching, and cramping (often at night) in the affected limb (upper-extremity PTS is discussed later in Upper-Extremity PTS). Symptoms differ from patient to patient, may be intermittent or persistent, usually worsen by the end of the day or with prolonged standing or walking, and improve with rest or limb elevation. Venous symptoms associated with the initial DVT can persist for several months and may transition to chronic symptoms without a symptom-free period. 8 PTS may also present as venous claudication, likely caused by persistent venous obstruction of a major venous confluence (iliofemoral or popliteal veins). Such patients report bursting leg pain during exercise that can resemble arterial claudication. 23 Typical signs of PTS are similar to those of other chronic venous diseases. These range from perimalleolar (or more extensive) telangiectasia, pitting edema, brownish hyperpigmentation of the skin, venous eczema, and secondary varicose veins to signs of more severe PTS such as atrophie blanche (white scar tissue), lipodermatosclerosis (fibrosis of subcutaneous tissues of the medial lower limb), and leg ulceration (Figure 1 ).
Pathophysiology of PTS
Although the pathogenesis of PTS is complex and has not been fully characterized, venous hypertension appears to play a central role ( Figure 2 ). Venous pressure is dependent on the weight of the blood column between the right atrium and the foot (hydrostatic pressure). Normally, when an individual is at rest in the supine position, venous pressure is low because dynamic pressure derived from the pumping action of the heart maintains movement of the blood through arteries and veins. 24 When an individual is upright (sitting or standing) but motionless, venous pressure is highest, increasing to up to 80 to 90 mm Hg. While an individual is walking at a rate of 1.7 mph, venous pressure is incrementally reduced to a mean of 22 mm Hg. 25 Blood is ejected by contraction of the leg muscles, which are assisted by competent venous valves working to return blood proximally from the distal leg to the heart after exercise, thus preventing reflux and limiting accumulation of blood in the lower-extremity veins. 24 Therefore, any damage to the venous valves impedes venous return to the heart, leading to venous hypertension and consequent leg pain and swelling. In the case of PTS, ambulatory venous hypertension can occur from outflow obstruction as a result of the thrombus or valvular incompetence (reflux). After DVT, recanalization of the thrombosed veins, which occurs through a combination of fibrinolysis, thrombus organization, and neovascularization, 26 is often incomplete, resulting in residual venous obstruction, which may interfere with calf muscle pump function and cause damage to venous valves, ultimately leading to venous valvular incompetence. In this situation, there is insufficient reduction in venous pressure with walking, resulting in ambulatory hypertension. 24 The literature on whether PTS development is predominantly the consequence of outflow obstruction, venous valvular reflux, or both is conflicting, which may reflect, in part, the limited ability to quantify venous obstruction and reflux. Prandoni et al 27 found that PTS developed more frequently in patients who had persistent venous obstruction within the first 6 months after an episode of acute proximal DVT (relative risk [RR], 1.6; 95% confidence interval [CI], 1.0-2.4), a result that was replicated by the same group in a second study. 28 Similarly, Roumen-Klappe et al 29 reported that persistent venous obstruction was an important predictor of PTS 3 months after DVT (RR, 1.7; 95% CI, 1.0-2.2). In the Catheter-Directed Venous Thrombolysis Trial (CaVenT), which assessed the efficacy of catheter-directed thrombolysis (CDT) using alteplase in patients with acute DVT extending above the popliteal vein, the absolute risk of PTS was reduced by 14.4% (95% CI, 0.2-27.9) in the CDT group. 30 Iliofemoral patency was noted in 65.9% of patients randomized to CDT compared with 47.4% of those who received conventional anticoagulant therapy, 30 but the prevalence of valvular reflux was similar in the 2 groups. 31 In contrast, Haenen et al 32 reported a significant positive correlation between increasing severity of PTS and prevalence of reflux in the proximal femoral vein (P<0.001), distal femoral vein (P<0.05), and popliteal vein (P<0.05). These investigators also noted that venous obstruction alone or in combination with reflux had no relation to the presence of severe PTS. Yamaki et al 33 and Asbeutah et al 34 have similarly reported that reflux appears to be more important than persistent obstruction in the pathophysiology of PTS.
Other models focus on vein wall damage and acute and chronic inflammation as potential drivers of PTS. 18, 35 Sustained venous hypertension can cause structural and biochemical abnormalities of the vein wall, resulting in pathological effects in the skin and subcutaneous tissues such as edema, hyperpigmentation, varicose veins, and ulceration. 24 Several studies have reported associations between elevated levels of various inflammation markers and PTS development 35, 36 (see Role of Biomarkers to Predict PTS).
Although the pathogenesis of PTS remains incompletely elucidated, there is mounting interest in the early use of pharmacomechanical therapy in patients with iliofemoral DVT to restore venous blood flow and to preserve valve function with the expectation that such treatment will reduce the risk of PTS (see Treatment of PTS). Further understanding of the pathophysiology of PTS will lead to more optimal prevention and management of the syndrome.
Diagnosis of PTS
There is no single gold standard test to diagnose PTS. PTS is diagnosed primarily on clinical grounds when characteristic (Table 2 ) occur in a patient with prior DVT. Because PTS is a chronic condition that often demonstrates a waxing-and-waning pattern, the recommendation is to wait at least 3 months for the initial pain and swelling associated with acute DVT to resolve; therefore, a diagnosis of PTS should generally be deferred until after the acute phase (up to 6 months) has passed.
Clinical Tools to Diagnose PTS
A number of clinical tools or scales have been used to help diagnose and define PTS. Of these, 3 were developed specifically to diagnose PTS after objectively diagnosed DVT: the Villalta scale, 37 Ginsberg measure, 9 and Brandjes scale. 38 The others, developed for chronic venous disease in general, include the CEAP (clinical, etiological, anatomic, pathophysiological) classification, 39 Venous Clinical Severity Score (VCSS), 40 and Widmer scale. 41 The general characteristics of each clinical scale are described below. Tables 3-5 show the individual components and scoring of the various scales.
Villalta Scale
The Villalta scale is a clinical measure that incorporates the assessment of 5 subjective (patient-rated) venous symptoms (pain, cramps, heaviness, paresthesia, and pruritus) and 6 objective (clinician-rated) venous signs (pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia, and pain on calf compression), as well as the presence or absence of ulcer, in the DVT-affected leg 13, 37 (Table 3 ). The Villalta scale shows good correlation with generic and disease-specific QoL scores, 3, 19 as well as anatomic and physiological markers of PTS. 27, 44 A potential shortcoming of the Villalta scale (which also applies to other scales discussed below) is its relative nonspecificity; symptoms and signs could be due, at least in part, to nonvenous conditions or primary venous insufficiency. 45 In addition, although the presence of ulcer is noted, ulcer size and number are not. Nonetheless, the Villalta scale has been widely and successfully used to diagnose PTS, 21, 35, 46, 47 to classify its severity, and to evaluate treatment, [48] [49] [50] including in randomized, controlled trials (RCTs). 30, 51 In an effort to standardize the definition of PTS for research purposes, the International Society on Thrombosis and Haemostasis Subcommittee on Control of Anticoagulation recommended the Villalta scale as the most appropriate measure to diagnose and rate the severity of PTS, 13 as has a recent systematic review. 52 Kahn et al 13 provide a more detailed description of the Villalta scale and recommendations on how to administer it.
Ginsberg Measure
The Ginsberg measure 9 defines PTS by the presence of daily leg pain and swelling that persists for at least 1 month, is typical in character (worse with standing or walking and relieved by rest or leg elevation), and occurs at least 6 months after acute DVT. This measure was used as the primary PTS outcome measure in the recently published Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) trial. 53 Although the measure does not rate the severity of PTS, it correlates well with QoL scores and identifies more severe PTS than the Villalta scale. 52, 54 Potential shortcomings include a lack of sensitivity for milder forms of PTS and the fact that it is not quantitative.
Brandjes Scale
The Brandjes scale, similar to the Villalta scale, assesses a number of subjective and objective criteria, including leg circumference. 38 On the basis of scores determined in 2 consecutive visits 3 months apart, patients are classified as having no PTS, mild to moderate PTS, or severe PTS. This scale was used to assess PTS in 1 study. 38 
Venous ulcer Absent Present
Total score of 0 to 4 indicates no postthrombotic syndrome (PTS); score of ≥5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of ≥15 or venous ulcer present, severe PTS.
Adapted from Guanella et al 42 with permission from Informa Health Care. Copyright © 2012, Informa Health Care. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation. 
CEAP Classification
The CEAP classification was developed to diagnose and compare treatment outcomes in patients with chronic venous disorders. 43 CEAP categorizes venous disease according to clinical, etiologic, anatomic, and pathophysiologic attributes. There are 7 clinical classes, which correspond with objective clinical signs (Table 4 ). Although CEAP has been used to diagnose PTS, 12, 29, 35, 55 there is no agreed-on cutoff that defines the diagnosis, 52 it has a limited ability to monitor change over time, and it does not incorporate assessment of PTS symptom severity. Therefore, CEAP is not an ideal scoring system to diagnose and follow up the course of PTS.
The VCSS
The VCSS (Table 5 ), 56 recently revised by Vasquez et al, 40 combines key elements of CEAP with additional criteria such as use of compression therapy and number and duration of ulcers, thus allowing assessment of change with treatment. The VCSS scoring system assesses the severity of 9 clinical signs of chronic venous disease. VCSS elements are weighted toward more severe manifestations, and only 1 symptom (pain) is assessed; hence, this measure has not been used in many studies to diagnose incident PTS.
Widmer Classification
The Widmer classification, developed to grade chronic venous disease into classes I, II, and III according to the presence of clinical signs, has also been used to diagnose PTS 41 and to assess the effectiveness of compression therapy in patients with stage I and II PTS. 57 A comparison of the various PTS classifications and their relationships with invasive venous pressure measurement was performed by Kolbach et al. 44 In general, agreement among the different clinical measures is modest. For example, there is poor to moderate agreement between the Villalta scale and CEAP, and VCSS shows poor correlation with other scoring systems. 44 A study by Kahn et al 54 found that the proportion of patients classified as having PTS according to the Villalta scale was almost 5 times higher than that classified by the Ginsberg measure (37% versus 8.1%, respectively), with the Ginsberg measure tending to be less sensitive for mild PTS. Jayaraj and Meissner 58 recently reported good correlation between the Villalta scale and VCSS for mild and moderate PTS but not for severe PTS.
The variability in the measures used to define PTS has limited the ability to compare results across studies. Because the Villalta scale was developed specifically for PTS and BMI indicates body mass index; CFV, common femoral vein; CI, confidence interval; CRP, C-reactive protein; dist, distal; DVT, deep vein thrombosis; FVIII, factor VIII; FII, G20210A prothrombin gene mutation; FVL, factor V Leiden; HR, hazard ratio; ICAM, intercellular adhesion molecule; IL-6, interleukin-6; INR, international normalized ratio; LMWH, low-molecular-weight heparin; OAC, oral anticoagulants; OR, odds ratio; prox, proximal; PTS, postthrombotic syndrome; RR, relative risk; TTR, time in the therapeutic range; VOR, venous outflow resistance; −, no apparent association; +/−, variable or inconsistent association; +, consistent association of low magnitude; and ++, consistent association of higher magnitude 
Objective Diagnosis of PTS
In patients with a characteristic clinical presentation of PTS but no history of previous DVT, compression ultrasonography can be done to look for evidence of prior DVT such as lack of compressibility of the popliteal or common femoral veins or reflux of venous valves on continuous-wave Doppler. 9, 59, 60 In carefully selected patients in whom iliac vein obstruction is suspected on clinical grounds (eg, chronic severe aching or swelling of the entire limb, lack of respiratory phasicity of the common femoral vein Doppler waveform), imaging of the iliac vein using cross-sectional modalities (computed tomography, magnetic resonance imaging) or contrast venography with or without intravascular ultrasound can be performed. In such patients, the imaging finding of iliac vein thrombosis can confirm the diagnosis of PTS and guide therapeutic options. However, venography is invasive, so it is not routinely recommended for patients with mild symptoms that do not significantly affect daily functioning. It is important to highlight that many patients have demonstrable residual venous abnormalities after DVT (eg, venous reflux, venous hypertension, internal venous trabeculation) yet have no symptoms of PTS.
In the absence of characteristic clinical features of PTS, PTS should not be diagnosed.
Risk Factors for PTS
To date, known risk factors can generally be divided into 1 of 2 categories: factors apparent at the time of DVT diagnosis and those that manifest during follow-up (Table 6 ).
PTS Risk Factors Apparent at the Time of DVT Diagnosis

Patient Characteristics
Elevated body mass index and obesity increase the risk of developing PTS by as much as 2-fold. 8, 10, [45] [46] [47] 63 Older age also increases the risk of PTS. 8, 11, 46, 47 There is no consistent association between sex and PTS; an almost equal number of studies have shown men or women to be at higher risk for PTS. 8 
Risk Factors Apparent During DVT Treatment and Follow-Up
Recurrent ipsilateral DVT has been shown in numerous studies to be an important risk factor for PTS. The variability in the magnitude of effect across studies (ORs, 1.6-10) is probably attributable to differences in study populations and definitions of PTS. However, all are consistent in showing ipsilateral recurrence to be predictive of future PTS (Table 6) . 7, 8, 47, 51, 73, 75 Residual thrombosis after treatment of DVT has also been shown to be a predictor of PTS. 27, 28, 62, 76 In patients with a first episode of DVT, the risk of PTS was 1.6-fold higher (95% CI, 1.0-2.5) in those with residual proximal thrombosis compared with those without this finding. 62 A recent study by Comerota et al 76 documented a statistically significant correlation between residual thrombus after CDT and PTS severity. This finding highlights the importance of preventing recurrent DVT and the need to critically evaluate the utility of therapeutic strategies aimed at restoration of venous blood flow as potential means of preventing PTS.
The contribution of residual vein thrombosis versus popliteal valve incompetence to the risk of PTS was recently assessed in 290 patients with a first episode of proximal DVT. 28 The RR of PTS (assessed with the Villalta scale) was 1.92 (95% CI, 1.39-2.64) in patients with residual vein thrombosis alone, 1.11 (95% CI, 0.66-1.89) in patients with popliteal valve incompetence, and 1.83 (95% CI, 1.26-2.66) in patients with both findings, suggesting that residual vein thrombosis is a stronger determinant of PTS.
In the Venous Thrombosis Outcomes (VETO) study, a prospective cohort study by Kahn et al, 8 the presence of residual venous symptoms and signs 1 month after DVT diagnosis was strongly predictive of subsequent PTS. Patients whose residual symptoms at 1 month were mild, moderate, or severe had average Villalta scores over 2 years of follow-up that were higher by 2, 5, and 7 points, respectively, compared with patients without residual symptoms at 1 month. This suggests that the pathophysiological progenitor of PTS occurs in the first few weeks after DVT.
Finally, 2 studies reported that subtherapeutic anticoagulation with warfarin (international normalized ratio [INR] <2.0) increased the risk of PTS. In 1 recent study, patients had an almost 2-fold increased risk of developing PTS if their INR during the first 3 months of therapy was subtherapeutic >20% of the time (OR, 1.84; 95% CI, 1.13-3.01). 74 These findings were consistent with an earlier study that reported that patients whose INR results were subtherapeutic >50% of the time had a 2.7-fold higher risk of PTS. 47
Risk Factors Not Likely to Be Associated With PTS
Total duration of anticoagulation does not appear to influence the risk of PTS. In a multicenter trial comparing 6 weeks and 6 months of warfarin treatment, the risk of PTS was similar in both groups. 11 Similarly, Stain et al 10 observed that duration of anticoagulant therapy (< 6, 6-12, or >12 months) did not influence the risk of PTS. Level of education and income were not significantly correlated with PTS, nor was the nature of the initial DVT event (provoked versus unprovoked). 10, 12, 44, 46, 51, 56, 72, 81 In some studies, asymptomatic DVT (eg, detected by systematic imaging in the course of a clinical trial) was associated with subsequent development of PTS, 70 whereas in others it was not. 71, 72 Finally, inherited or acquired thrombophilia has generally not been shown to increase the risk of developing PTS, 10, 45, 46, 51, 81 although 1 study showed a protective effect. 63 In summary, key risk factors for PTS include older age, higher body mass index, recurrent ipsilateral DVT, more extensive DVT, greater symptom severity at 1 month, and subtherapeutic anticoagulation, especially in the first few months after DVT. Further research on predictors of PTS is needed, including the development and validation of PTS risk prediction models. Whether risk factor modification such as weight reduction may have a role in preventing PTS has not been studied.
Role of Biomarkers to Predict PTS
Recent research efforts have focused on the role of inflammatory biomarkers such as interleukin-6, C-reactive protein, and intercellular adhesion molecule-1 as predictors of PTS. Shbaklo et al 36 reported that patients with PTS had significantly higher mean levels of interleukin-6 and intercellular adhesion molecule-1 than those without PTS. Roumen-Klappe et al 35 noted that higher levels of interleukin-6 and C-reactive protein were associated with greater venous outflow resistance 3 months after DVT, but their association with clinical PTS was weak or absent. In a recent prospective cohort study, C-reactive protein levels >5 mg/L 12 months after the index DVT independently predicted PTS (OR, 8.0; 95% CI, 2.4-26.4). 75 In 2 studies, persistently elevated levels of D-dimer, an indirect marker of coagulation activation, were predictive of PTS when measured at various intervals after DVT, 10, 78 especially when measured when the patient was off anticoagulant treatment. It is not yet known whether the aforementioned biomarkers may have clinical utility to identify patients with acute DVT who are at risk for PTS.
Prevention of PTS
Importance of Primary and Secondary Prevention of DVT to Prevent PTS
Primary Prevention
Because PTS is a consequence of DVT and thromboprophylaxis is an effective means of preventing DVT, it is clear that use of pharmacological or mechanical thromboprophylaxis in high-risk patients and settings as recommended in evidencebased consensus guidelines [82] [83] [84] will prevent cases of PTS.
Secondary Prevention
Although thromboprophylaxis is effective, its use reduces the incidence of venous thromboembolism by only one half to two thirds. Moreover, nearly 50% of venous thromboembolism events occur unpredictably and are therefore not preventable with thromboprophylaxis. Hence, strategies that focus on preventing the development of PTS after DVT are more likely to be effective in reducing the frequency of PTS than are attempts to prevent the index DVT. Because ipsilateral DVT recurrence is an important risk factor for PTS, preventing recurrent DVT by providing anticoagulation of appropriate intensity and duration for the initial DVT is an important goal. 85 In addition, appropriate thromboprophylaxis should be used when clinically warranted if long-term anticoagulation is discontinued.
Recommendations for Primary and Secondary Prevention of DVT to Prevent PTS
Use of thromboprophylaxis in patients at significant risk for DVT is recommended as a means of preventing PTS (Class I; Level of Evidence C). 2. Providing anticoagulation of appropriate intensity and duration for treatment of the initial DVT is recommended as a means of reducing the risk of recurrent ipsilateral DVT and consequent PTS (Class I; Level of Evidence B).
Optimizing Anticoagulation Delivery to Prevent PTS
As discussed, subtherapeutic anticoagulation with vitamin K antagonists has been associated with the development of PTS, 47, 74 with an almost 3-fold higher risk in those who had an INR <2.0 for >50% of the time. This occurred in about one third of patients, usually in the first few weeks of treatment. A dose-response effect was noted such that patients who spent more time in the subtherapeutic INR range had the highest incidence of PTS. There has been interest in whether low-molecular-weight heparins (LMWHs), which have anti-inflammatory and anticoagulant properties, 86 could have a role in preventing PTS. In a systematic review of 5 randomized trials that compared longterm (≥3 months) LMWH with warfarin for DVT treatment, Hull et al 77 reported a risk ratio of 0.66 (95% CI, 0.57-0.77) in favor of LMWH for complete recanalization of thrombosed veins, and LMWH-treated patients had a lower incidence of venous ulceration. It should be noted that none of the included trials assessed PTS with accepted, validated clinical scales. Furthermore, although LMWH is safe and effective, it is costly and requires administration by daily subcutaneous injection.
As noted above, Kahn et al 8 reported that the severity of venous symptoms and signs as early as 4 weeks after DVT were strongly predictive of the subsequent development of PTS. Together with the observation that inadequate initial oral anticoagulation increases the risk of PTS, these findings suggest that the treatment delivered during the first few weeks after DVT may be fundamental to determining long-term outcome, perhaps by tilting the physiological balance in favor of endogenous thrombus reduction, by preventing or reducing damage to the valves and microcirculation, or by limiting inflammation. The interesting hypothesis has been raised that new oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban, with their rapid onset and more predictable pharmacokinetics than vitamin K antagonists, could be associated with a reduced incidence of PTS. 87 However, this has not yet been tested. 
Compression to Prevent PTS
Until recently, elastic compression stockings (ECS) have been considered a mainstay for PTS prevention despite sparse and conflicting data supporting their use. Six RCTs of the use of ECS to prevent PTS that include data on a total of nearly 1500 patients have been published. Summaries of these trials are given in Table 7 . 9, 12, 38, 51, 53, 88 Brandjes et al 38 In contrast to the trials above that initiated stockings soon after DVT diagnosis, 2 studies enrolled patients 6 months 12 and 1 year 9 after DVT diagnosis. In the first study, all patients wore ECS for the first 6 months after DVT diagnosis, and in the second study, patients did not begin to use ECS until study enrollment, 1 year after DVT diagnosis. In neither study did the use of knee-high 26-to 36-mm Hg or 20-to 30-mm Hg ECS, respectively, reduce the rate of PTS compared with no stockings, suggesting that extending the use of stockings beyond the first 6 months or late initiation of stockings is not of benefit to reduce the incidence of PTS.
Partsch et al 88 compared early ambulation in combination with compression stockings (n=18) or Unna boots (n=18) with bed rest and no compression (n=17) in patients with acute DVT. All patients wore ECS for at least the first year of follow-up. At 2 years, the 2 early ambulation groups had lower Villalta scores, although the number of patients who met Villalta criteria for PTS was not reported. Given the design of this study, it cannot be discerned whether early compression or early ambulation was responsible for the apparent benefit.
The SOX trial was the only multicenter, double-blind, placebo-controlled trial of ECS. 53 This trial enrolled 806 patients an average of 4.7 days after a first episode of symptomatic proximal DVT and randomized them to 30-to 40-mm Hg knee-high ECS or placebo stockings with no compression for 2 years. The primary outcome was the Ginsberg definition of PTS, namely persistent daily leg pain and swelling for at least 1 month. There was no statistically significant difference in the primary outcome between those randomized to active ECS and those randomized to placebo (hazard ratio, 1.13; 95% CI, 0.73-1.76). 53 Secondary analyses showed no effect of active ECS on PTS as defined by the Villalta scale, PTS severity, venous ulcers, venous thromboembolism recurrence, venous valvular reflux, or QoL. Subgroup analyses did not identify benefit of active ECS for subgroups defined by age, sex, body mass index, extent of DVT, or frequency of stocking use. These results suggest that the use of ECS does not alter the natural history of the development of PTS after DVT and that the benefit of ECS reported in previous studies may have been due, at least in part, to reporting or observer bias as a consequence of their open-label design. Alternatively, the placebo stockings used in the SOX study may have had some therapeutic effect. Adverse events associated with stocking use are rare. In the study by Prandoni et al, 51 itching, erythema, or discomfort (6%) and difficulty putting on the stockings (1%) were the principal recorded complaints. Compliance, which was defined as wearing stockings at least 80% of the time over the 2-year study period, was 93% in that trial. No serious adverse events were attributed to stockings in the SOX trial, and minor adverse events such as rash or itching occurred in <2% of patients in both groups. At 2 years, 56% of patients reported frequent use of their stockings, defined as wearing them for ≥3 days each week. Although not reported in these trials, it should be noted that ECS may aggravate symptoms in patients with arterial inflow limitation from peripheral arterial disease; hence, caution is urged in prescribing ECS to such patients.
On the basis of existing evidence, ECS are a low-risk intervention that may be useful for controlling the symptoms of acute DVT. However, whether ECS prevent PTS is now in doubt because the highest-quality evidence provided by the SOX trial suggested no benefit.
Recommendations for Compression to Prevent PTS
The effectiveness of ECS for PTS prevention is uncertain, but application of ECS is reasonable to reduce symptomatic swelling in patients with a diagnosis of proximal DVT (Class IIb; Level of Evidence A).
Thrombolysis/Endovascular Therapies to Prevent PTS
Systemic anticoagulation alone does not reduce the risk of PTS. Earlier and more complete thrombus clearance producing an "open vein" can relieve venous outflow obstruction, preserve valvular function, and reduce venous hypertension. 76, 89 Therefore, from a pathophysiological standpoint, pharmacological thrombolysis, mechanical thrombectomy, or their combination is attractive for PTS prevention in patients with acute proximal DVT. 90, 91 However, the evidence for thrombolysis, whether systemic or CDT, or pharmacomechanical CDT (PCDT) for the prevention of PTS is currently insufficient to support its routine first-line use in most patients with DVT. 85, 90, 92 Systemic thrombolysis as an upfront treatment for DVT is not recommended for the prevention of PTS. Although several studies have compared systemically delivered thrombolytics with anticoagulation alone for DVT, few evaluated the occurrence of PTS as a primary outcome. [93] [94] [95] [96] Although this limited number of studies suggested a reduction in PTS, the risk of major bleeding was greater with systemic thrombolysis than with anticoagulation alone or CDT. 96, 97 Moreover, there is a nontrivial failure rate of systemic thrombolysis resulting, in part, from the poor concentration and penetration of thrombolytics within the thrombus itself. 98 CDT and PCDT evolved to overcome the limitations of systemic thrombolysis and the invasiveness of surgical thrombectomy. 90, 99 However, given the known risks of thrombolytic therapy and the uncertainty surrounding the estimates of risks and benefit from the many CDT/PCDT studies that were of low to medium quality, CDT and PCDT are not currently recommended for routine first-line use for the purpose of PTS prevention in the general DVT patient population. Rather, these are promising techniques that should be considered in experienced centers for selected patients with acute symptomatic iliofemoral DVT (defined as DVT involving the common femoral vein or iliac vein, with or without involvement of additional veins) who, after careful evaluation, are considered to be at low risk for bleeding complications. 100 It should be noted that CDT or PCDT may be indicated in specific situations apart from PTS prevention such as for limb salvage in the rare patient with acute limb-threatening DVT, for early symptom relief in patients with particularly severe pain and swelling resulting from iliofemoral DVT or rapid DVT progression despite initial anticoagulation, or for organ salvage in patients with acute inferior vena cava thrombosis compromising end organs (eg, extending to renal vein thrombosis). The reader is referred to other guidelines for recommendations in these situations. 92, 100, 101 Most of the evidence supporting CDT or PCDT for the prevention of PTS stems from nonrandomized, single-center studies or registries. 76, 96, [102] [103] [104] [105] [106] However, the recent Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis (CaVenT) and Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trials provide more robust, although still limited, data on CDT and PCDT. CaVenT was an openlabel RCT of 209 patients with acute proximal DVT comparing CDT plus standard anticoagulation with standard anticoagulation alone. There was a statistically significant (P=0.047) 26% relative reduction in risk of PTS at 2 years associated with CDT. However, 41% of CDT patients still developed PTS, indicating that CDT does not eliminate the risk of PTS. In addition, imbalances in the adequacy of anticoagulation and use of ECS between groups (both greater in the CDT group) may have influenced the results. 30 The TORPEDO trial evaluated PCDT plus anticoagulation versus anticoagulation alone in 183 patients with symptomatic DVT and found that PCDT significantly reduced the risk of PTS (7% versus 30%; P<0.001). 107 This study had a number of limitations, including the use of a nonvalidated measure of PTS, lack of blinding precautions for the clinical assessments, systematic differences in the use of antiplatelet therapy in the 2 treatment arms, and adjudication of crossovers as treatment failures. The multicenter, National Institutes of Health-sponsored Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial (anticipated enrollment, n=692; expected completion, 2016) will be the largest and most definitive study to date to address the role of CDT and PCDT in acute proximal DVT for the prevention of PTS. 108 Table 8 summarizes the CaVenT, TORPEDO, and ATTRACT trials.
Surgical thrombectomy might be considered in select patients with extensive acute proximal DVT who are not candidates for CDT or PCDT because of bleeding risk (Figure 3) . In a recent meta-analysis, 8 studies, all from the 1970s through 1990s, were identified that addressed surgical thrombectomy versus systemic anticoagulation for the prevention of PTS. In October 28, 2014 the pooled analysis of 611 patients, surgical thrombectomy was associated with a 33% RR reduction (95% CI, in the incidence of PTS. 109 However, we underline that there have not been any contemporary trials comparing surgical thrombectomy with systemic anticoagulation or CDT/PCDT.
For further discussion and procedural details for CDT, PCDT, surgical thrombectomy, and use of inferior vena cava filters in the management of acute iliofemoral DVT, the reader is referred to a recent American Heart Association scientific statement by Jaff et al. 100 †PEVI group: procedure performed within 24 hours of presentation and inititation of anticoagulation. All patients received inferior vena cava filter. Treatment consisted of ≥1 of a combination of thrombectomy, manual thrombus aspiration, balloon venoplasty, stenting, or local catheter-directed low-dose thrombolytic therapy with tPA 1 mg/h for 20 to 24 hours, followed by 81 mg aspirin per day for ≥6 months and, in the case of stent placement, clopidogrel 75 mg/d for 2 to 4 weeks.
Recommendations for Thrombolysis and Endovascular Approaches to Acute DVT for the Prevention of PTS
CDT and PCDT, in experienced centers, may be considered in select patients with acute (≤14 days) symptomatic, extensive proximal DVT who have good functional capacity, ≥1-year life expectancy, and low expected bleeding risk (Class IIb; Level of Evidence B). 2. Systemic anticoagulation should be provided before, during, and after CDT and PCDT (Class I, Level of Evidence C).
Balloon angioplasty with or without stenting of underlying anatomic venous lesions may be considered after CDT and PCDT as a means to prevent rethrombosis and subsequent PTS (Class IIb; Level of Evidence B). 4. When a patient is not a candidate for percutaneous CDT or PCDT, surgical thrombectomy, in experienced centers, might be considered in select patients with acute (≤14 days) symptomatic, extensive proximal DVT who have good functional capacity and ≥1year life expectancy (Class IIb; Level of Evidence B). 5. Systemic thrombolysis is not recommended for the treatment of DVT (Class III; Level of Evidence A).
Treatment of PTS Graduated Stockings and Intermittent Compression to Treat PTS
A number of compression-based therapies have been used in patients with PTS with the goals of reducing symptoms (particularly limb swelling) and improving daily functioning, but few controlled studies of their effectiveness have been performed. Anecdotally, some patients describe improvement with the use of compression, but the published studies have methodological limitations and statistical imprecision that preclude confident conclusions about their effectiveness in patients with PTS. Accordingly, the recommendations below are based primarily on the low risk of harm and the possibility of benefit to at least some patients with PTS.
Graduated ECS
Two small, randomized trials comprising a total of 115 patients have evaluated the ability of 30-to 40-mm Hg graduated ECS to reduce symptoms in patients with PTS. 9, 49 In 1 study, patients with PTS were randomized to receive active 30-to 40-mm Hg stockings (knee-high or thigh-high stockings) versus placebo stockings and were followed up for clinical change every 3 months. 9 The proportions of patients exhibiting failure of therapy were similar in both arms (61.1% active stockings versus 58.8% placebo; P=NS). The second study was an open-label, assessor-blind RCT in which patients with PTS were randomized to wear or not to wear 30-to 40-mm Hg knee-high ECS. 49 No benefit was observed with use of ECS.
No studies have directly addressed the comparative efficacy of thigh-high versus knee-high ECS to treat PTS. Although most patients exhibit some degree of compliance with ECS with education on their use, limitations of ECS can include patient nonadherence resulting from difficulty in donning the garments, discomfort, allergic hypersensitivity of the skin, and cost. However, because the risk of major harm with ECS therapy is low and some patients report clinical improvement with their use, a trial of ECS may be reasonable in patients with PTS and without contraindications.
Intermittent Compression Devices
Two small, crossover RCTs evaluated the use of intermittent compression devices for the treatment of PTS. One study of 15 patients with severe PTS found that a 4-week period of daily use of an intermittent pneumatic compression device at 50 mm Hg improved edema in 80% of the patients. 110 Disadvantages of intermittent pneumatic compression therapy are its expense and inconvenience, in particular, the need to pump the affected limb for several hours each day. The second study evaluated a lightweight, portable, battery-powered, cuff-like compression device (VenoWave device). 50 In this 2-center, placebo-controlled, double-blind, crossover RCT of 32 patients with severe PTS and no ulcer, 31% of patients who used the device daily for 8 weeks were clinically improved compared with 13% in the placebo arm (P=0.11).
Despite the statistical imprecision of these estimates of efficacy resulting from the small numbers of patients studied, the potential for benefit is likely to outweigh harm. Hence, a trial of an intermittent compression device may be reasonable for patients with moderate or severe PTS and edema.
Recommendations for the Use of Graduated ECS and Intermittent Compression to Treat PTS
A trial of ECS may be considered in patients with PTS who have no contraindications (eg, arterial insufficiency) (Class IIb; Level of Evidence C). 2. For patients with moderate or severe PTS and significant edema, a trial of an intermittent compression device is reasonable (Class IIb; Level of Evidence C).
Pharmacotherapy to Treat PTS
Only 4 randomized trials have been performed to evaluate the effectiveness of pharmacological therapy for PTS: 3 parallel trials 49, 111, 112 and 1 crossover study. 113 The drugs evaluated were rutosides (thought to reduce capillary filtration rate and microvascular permeability to proteins), defibrotide (downregulates plasminogen activator inhibitor-I release and upregulates prostacyclin, prostaglandin E2, and thrombomodulin), and hidrosmin (unknown mechanism of action). 114 The main features of these studies are shown in Table 9 . de Jongste et al 111 reported statistically significant improvement in leg tiredness in patients treated with rutosides compared with patients treated with placebo, but pain, heaviness, and swelling were only moderately relieved. Monreal et al 113 showed that both hidrosmin and rutosides reduced symptoms but that hidrosmin produced greater improvement. Statistically significant improvement in pain and edema scores was observed by Coccheri et al 112 with defibrotide versus placebo, whereas claudication, skin pigmentation, and lipodermatosclerosis were unchanged. Finally, a similar proportion of patients treated with compression stockings alone, rutosides alone, and a combination of compression stockings and rutosides showed symptom improvement (70%, 65%, and 63%, respectively) or deterioration (15%, 23%, and 23%) in the study by Frulla et al. 49 Notably, in the only study in which follow-up continued for 6 additional months after treatment completion, the drug effect virtually disappeared. 113 Three of 4 studies reported on side effects, which were mostly mild and balanced between groups. 49, 111, 112 In the de Jongste et al 111 study, 7 of 41 patients (17%) in the rutosides group and 4 of 42 (12%) in the placebo group reported headache, hair loss, swollen fingers, muscle stiffness, rash, or dizziness. In the Coccheri et al study, 112 3% in both groups reported nausea, vomiting, or syncope, and a case of laryngeal edema occurred in the defibrotide group. Gastric pain was reported by 6 of 80 patients (8%) taking rutosides in the study by Frulla et al. 49 Because drug treatment was usually of short duration, potential long-term side effects are unknown.
Overall, there is low-quality evidence to support the use of venoactive drugs (rutosides, hidrosmin, and defibrotide) to treat PTS, and all studies present a high degree of inconsistency and imprecision. 114 More rigorous studies using 
Exercise Training to Treat PTS
Exercise does not appear to aggravate leg symptoms after DVT or to increase the risk of PTS. 79, 115 Indeed, many patients with PTS report improvement in their symptoms with exercise, which may be related to improved calf muscle function and ejection of venous blood from the limb. Two small trials have assessed the potential benefits of exercise in patients with PTS. In a study of 30 patients with chronic venous insufficiency (half had prior DVT), a 6-month leg muscle strengthening exercise program was associated with improved calf muscle pump function and dynamic calf muscle strength. 116 In a 2-center Canadian pilot study, 42 patients with PTS were randomized to 6 months of exercise training (including components to increase leg strength and flexibility and overall cardiovascular fitness) or control. Exercise training was associated with improvement in PTS severity, QoL, leg strength, and leg flexibility, and there were no adverse events. 48 In summary, although the role of exercise training to prevent or treat PTS is not definitively established, available data suggest that exercise does not harm and may benefit patients with DVT and PTS. Further research on the role of exercise after DVT is warranted. 
Recommendations for Exercise Training to
Venous Ulcer Management
Up to 10% of patients with DVT develop severe PTS, which can include leg ulcers (Figure 4 ). The probability of developing an ulcer increases with PTS duration, with up to 5% of patients with DVT having ulcers by 10 years. 11 Leg ulcers are costly, slow to heal, and disabling and reduce QoL. 16 The mainstay of treatment for venous ulcers is compression therapy. A systematic review of 7 RCTs reported that chronic venous ulcers healed more quickly with compression compared with primary dressings alone, noncompression bandages, and usual care without compression. 118 This review also suggested that single-component compression may be less effective than multicomponent compression and that multicomponent compression systems containing an elastic bandage are more effective than those composed mainly of inelastic constituents.
There has been interest in the use of pentoxifylline, a hemorheological agent that increases microcirculatory blood flow and ischemic tissue oxygenation, to treat venous ulcers. 119 A meta-analysis of 11 trials reported that pentoxifylline 400 mg 3 times daily was more effective than placebo for complete healing of or significant improvement in ulcer (RR, 1.70; 95% CI, 1.30-2.24), and pentoxifylline plus compression was more effective than placebo plus compression (RR, 1.56; 95% CI, 1.14-2.13). 120 However, more adverse effects, mostly gastrointestinal (eg, nausea, indigestion, diarrhea), were reported in those receiving pentoxifylline (RR, 1.56; 95% CI, 1.10-2.22).
Other important measures to treat venous ulcers include maintaining a moist environment to optimize wound healing, providing a protective covering, controlling dermatitis, and aggressively preventing and treating infection. 121, 122 The role of exercise in healing venous ulcers is unknown. Exercise increases venous hypertension, theoretically worsening the conditions leading to ulceration. However, as discussed above, some patients with PTS note improvement in their symptoms with exercise, and supervised calf muscle exercise has been associated with improved hemodynamics in patients with venous ulcers. 116 More work is needed to determine whether exercise can help speed ulcer healing.
Finally, the role of surgical and endovascular procedures to remove or ablate incompetent superficial veins in the treatment of venous ulcers remains controversial. [123] [124] [125] [126] [127] Neovalve reconstruction may be considered as a surgical treatment for refractory venous ulcers. A study by Lugli et al 128 
Recommendations for Venous Ulcer Management
Compression should be used to treat venous ulcers in preference to primary dressing alone, noncompression bandage, or no compression (Class I; Level of Evidence A).
Multicomponent compression systems are more effective than single-component systems (Class I; Level of Evidence B).
Pentoxifylline can be useful for treating venous ulcers on its own or with compression (Class IIa; Level of Evidence A). 4. Neovalve reconstruction may be considered in patients with refractory postthrombotic venous ulcers (Class IIb; Level of Evidence C).
Endovascular and Surgical Treatment for PTS
Surgical or endovascular procedures to treat appropriately selected patients with PTS have potential to decrease postthrombotic morbidity attributable to deep venous obstruction or venous valve incompetence (Table 10 ). However, welldesigned studies have not been performed because experience with these procedures is limited and only the most severely affected patients are treated. Furthermore, some of the published experience predates the development of objective reporting standards for outcome assessment of patients undergoing procedures for chronic venous disease. October 28, 2014
As a first principle, detection and elimination of iliac vein obstruction may be worth considering for patients with moderate to severe PTS. Below, we describe the endovascular and surgical means to do this. An important consideration when evaluating procedural results is that there often is uncorrected disease distal to the most proximal reconstruction, which will mitigate the clinical response to the procedure. Interventions to correct reflux might be considered in a highly symptomatic patient once it is known that the iliac vein is open.
Infrainguinal Venous Obstruction
Saphenopopliteal or Saphenotibial Bypass
Using the patent saphenous vein to bypass an occluded femoral or popliteal venous segment was initially reported by Warren and Thayer 129 and subsequently by Husni 130 and others. [131] [132] [133] [134] [135] [136] The total number of patients reported is only 125, with followup ranging from 6 to 125 months. Bypass patency ranges from 50% to 97%, and clinical benefit is reported in 31% to 75%. The most contemporary series by Coleman et al 137 confirms a primary patency rate of 69%; 82% experienced complete or nearly complete resolution of venous claudication; and 59% experienced healing of their ulcers.
Iliofemoral Obstruction
Femoro-Femoral Bypass Palma and Esperon 138 were the first to report autogenous femoro-femoral bypass using the contralateral saphenous vein in patients with unilateral iliac vein obstruction; reports from others followed. [131] [132] [133] [134] [135] [136] [139] [140] [141] [142] After follow-up ranging from 6 to 144 months, autogenous bypass patency ranged from 37% to 100%, and 25% to 100% had clinical improvement. Prosthetic femoro-femoral bypasses were used in patients without adequate saphenous veins. 134, 139, [143] [144] [145] [146] [147] [148] After follow-up ranging from 1 to 123 months, patency and clinical success were 25% to 100%. Of note, reports with the best patency and clinical success had the smallest number of patients and shortest follow-up.
Garg et al 149 reported 26 patients undergoing femoro-iliac/ iliocaval bypass and 9 patients having femoro-caval bypass. At a median follow-up of 41 months, 53% of patients had no or minimal swelling and no activity limitations. Ulcers were healed in 83% of patients (10 of 12 patients) at 12 months, but half recurred at a mean of 48 months. Procedure type significantly correlated with persistent postthrombotic symptoms: relative odds were 0.5 in femoro-femoral bypasses, 0 in short bypasses, 0.6 in femoro-caval bypasses, 3 in complex bypasses, and 7 in hybrid reconstructions.
Endovascular Procedures for Iliocaval Obstruction
Central venous outflow obstruction of the iliofemoral venous segment results in the highest venous pressures and most severe PTS morbidity. A number of reports describe the technical success rate and short-term outcome after percutaneous relief of iliac vein obstruction. The largest, most carefully studied cohort was that of Neglen et al, 150 who reported results of venoplasty and stenting in 464 limbs of patients with PTS followed up for at least 5 years. Ulcer healing occurred in 55%. Resting arm-foot pressure differential and QoL significantly improved after venoplasty and stenting. Procedure-related thrombosis occurred in 2.6%.
Complex Reconstructions
Hybrid Surgical and Endovenous Iliofemoral/Caval Reconstruction Patients with common femoral vein and iliac vein segment with or without caval obstruction have been treated with surgical endophlebectomy of the common femoral vein with patch angioplasty and endoluminal balloon venoplasty and stenting of the iliac veins and vena cava. An adjunctive arteriovenous fistula is used to maintain patency. Operative disobliteration of the common femoral vein is performed to drain the infrainguinal venous system more effectively and to provide inflow to the recanalized iliac veins. Comerota 151 recently reported results of 16 limbs (14 patients) with incapacitating PTS involving the common femoral and iliac veins (12 patients) and bilateral common femoral vein and iliocaval segments (2 patients). Seven procedure-related complications occurred: bleeding (3), thrombosis (3), and acute lymphedema (1). All patients had at least 6 months of followup (mean, 26 months). All 3 patients with recalcitrant venous ulcers experienced healing without recurrence. QoL, Villalta, and VCSS scores significantly improved after the procedure.
Surgical Procedures to Correct Reflux
Segmental Vein Valve Transfer: Axillofemoral/Popliteal Transplantation or Venous Transposition
Transplanting a segment of axillary vein with a competent valve or valves to an incompetent postthrombotic infrainguinal vein or transposing an incompetent femoral vein below a competent profunda vein valve or saphenous vein valve has been shown to reduce the clinical severity of chronic venous disease. A report by Masuda and Kistner 152 summarized long-term outcomes (follow-up, 4-21 years; mean follow-up, 11 years). Thirty-seven percent of patients (6 of 16 patients) with PTS versus 73% of patients (16 of 22 patients) with primary venous insufficiency had good to excellent results, defined by ability to resume full activity, either with stockings or without stockings. Neovalve reconstruction for patients with refractory venous ulceration is discussed above in Venous Ulcer Management.
Endovascular Approaches to Address Reflux
Two studies have reported the use of endovenous thermal ablation to eliminate saphenous vein reflux as a source of venous hypertension in patients with PTS who continue to be symptomatic after iliac vein obstruction has been addressed. 117, 153 Both suggest that at least some patients experience symptom improvement with this approach, but both studies had significant methodological limitations. Hence, this approach cannot be strongly recommended at present. Prospective studies of this and other endovascular strategies to treat PTS are needed.
Harms of Endovascular and Surgical Approaches
Complications associated with endovascular and open surgical venous reconstruction depend on the magnitude of the underlying disease and patient comorbidities. Focal, singlesegment obstruction is generally associated with good success and low complication rates. Conversely, patients with multilevel venous occlusion who require open surgical procedures as part of the overall treatment strategy face acute failure rates of up to 10% to 20%, with a 10% rate of hemorrhagic complications and 5% to 10% rate of wound complications. 154, 155 
Summary
Open surgical and endovenous procedures that correct central postthrombotic venous occlusion or infrainguinal venous valvular incompetence may be offered to patients with severe PTS in an attempt to reduce postthrombotic morbidity and to improve QoL. However, Level of Evidence A data do not exist; therefore, only weak recommendations (mostly Level of Evidence C) can be made.
We emphasize that outcomes of these procedures are highly dependent on operator (surgical) expertise and that, if not available locally, referral to a center with expertise is recommended. Selection of patients for these procedures should take into account the surgical risk, clinical severity of PTS, specific venous anatomy, and expected life span.
Recommendations for Endovascular and Surgical Treatment of PTS
For the severely symptomatic patient with iliac vein or vena cava occlusion, surgery (eg, femoro-femoral or femoro-caval bypass) (Class IIb; Level of Evidence C) or percutaneous endovenous recanalization (eg, stent, balloon angioplasty) (Class IIb; Level of Evidence B) may be considered. 2. For severely symptomatic patients with postthrombotic occlusion of their common femoral vein, iliac vein, and vena cava, combined operative and endovenous disobliteration may be considered (Class IIb;
Level of Evidence C).
For severely symptomatic patients with PTS, segmental vein valve transfer or venous transposition may be considered (Class IIb; Level of Evidence C).
Special Populations
Upper-Extremity PTS
Upper-extremity DVT (UEDVT) comprises DVT of the subclavian, axillary, or brachial veins. Although PTS develops after UEDVT, reported incidences are variable, in part because there is no accepted standard for its diagnosis, and range from 7% to 46%, with a systematic review of 7 studies reporting a weighted mean incidence of 15%. 156 Risk factors for upperextremity PTS are not well characterized. In a prospective study of 53 patients with first UEDVT followed up for 5 years, more than a quarter of patients developed PTS by 2 years. Residual thrombus on ultrasound predicted the development of PTS (hazard ratio, 4.0; 95% CI, 1.1-15.0). Subclavian and axillary thromboses were also associated with PTS but did not achieve statistical significance (hazard ratio, 2.9; 95% CI, 0.8-10.7). 157 Of interest, the incidence of PTS appears to be lower after catheter-associated UEDVT than after spontaneous UEDVT or UEDVT resulting from extrinsic compression. 158 As with lower-extremity PTS, upper-extremity PTS can reduce QoL and upper-extremity function. 159, 160 Furthermore, dominant-arm PTS appears to be associated with worse QoL and disability than nondominant-arm PTS. 159 Data to guide the management of upper-extremity PTS are sparse. There have been no trials of compression sleeves or bandages to prevent or treat upper-extremity PTS. Similarly, it is uncertain whether thrombolysis or endovascular or surgical treatment of UEDVT results in lower rates of PTS than standard anticoagulation. A prospective evaluation of a small group of patients treated for effort-induced UEDVT with thrombolysis, thoracic inlet decompression, percutaneous transluminal angioplasty, and subclavian vein stenting reported that those with complete venous patency after treatment were asymptomatic on follow-up, 161 and a retrospective study of 30 patients with UEDVT treated with catheter-directed lysis showed that none developed severe PTS and 6 (21%) developed mild PTS. 162 However, another study comparing systemic thrombolysis with anticoagulation alone in 95 patients with UEDVT showed similar rates of PTS in both groups. 163 Further study is needed to determine the incidence and risk factors for upper-extremity PTS, to develop a standardized scoring system for its diagnosis, and to test modalities to prevent and manage this condition.
Because of a lack of studies on compression bandages, compression sleeves, or venoactive drugs to prevent or treat PTS after UEDVT, it is not possible to make specific recommendations on the prevention or treatment of upper-extremity PTS. Please refer to the Recommendations for Primary and Secondary Prevention of DVT to Prevent PTS and the Recommendations for Optimizing Anticoagulation Delivery to Prevent PTS for general approaches to preventing PTS. Please refer to Kearon et al 85 for management of acute UEDVT.
Pediatric PTS
A systematic review of the literature revealed 19 studies reporting the frequency of PTS in children with DVT. 164 Among a total of 977 patients with UEDVT/lower-extremity DVT, the weighted mean frequency of PTS was 26% (95% CI, [23] [24] [25] [26] [27] [28] . When restricted to the 9 prospective analyses, [165] [166] [167] [168] [169] [170] [171] [172] [173] this frequency was 17% (95% CI, [14] [15] [16] [17] [18] [19] [20] . Only 1 prospective study has subsequently been published, in which the cumulative incidence of PTS was 23% after a follow-up period ranging from 1 to 5 years. 174 Variation in estimates of PTS frequency across studies may be attributable to the heterogeneity of study designs and methods of PTS measurement and variable intervals from DVT occurrence to PTS assessment. In addition, although a recent retrospective study suggested that change in PTS severity (as measured by modified Villalta score) is common over time, 175 it is unclear whether this is a true reflection of natural history or is explained by poor testretest reliability of the instrument itself.
In its recent recommendations on definition of pediatric PTS, 176 the Pediatric/Perinatal Subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee concurred with the Scientific and Standardization Committee's adult PTS recommendation that evaluation of PTS after lower-extremity DVT should consist of both objective (ie, signs) and subjective (ie, symptoms) criteria but recognized limitations in the degree to which subjective criteria can be reliably assessed in pediatrics, particularly among young children. Nevertheless, for standardized pediatric PTS assessment, it recommended the use of either the Manco-Johnson instrument (training video is available at www.kids-dott.net) or the modified Villalta score. 177 Given the lack of published data on test-retest reliability of pediatric PTS assessment, it was also recommended that a diagnosis of definitive PTS in children be restricted to concordance on 2 independent PTS evaluations performed at least 3 months apart.
Lack of a pediatric, venous disease-specific QoL outcome instrument is an additional limitation in understanding the physical and psychosocial impacts of PTS in children. National Institutes of Health-funded efforts are underway to evaluate associations between pediatric PTS instrument findings and QoL outcome measures after UEDVT/lower-extremity DVT in children (M.J. Manco-Johnson, N.A. Goldenberg, and S.R. Kahn, personal communication, April 25, 2014) .
Limited evidence exists on the prognostic factors for PTS in children. An early study implicated elevated levels of hypercoagulability and inflammation biomarkers (eg, factor VIII, D dimer) as predictors of poorer outcome, 173 and a small prospective series suggested a protective effect of acute thrombolytic approaches to treat occlusive proximal limb DVT. 172 Recently, a 2-institution cohort study reported preliminary findings that the acute presence of the lupus anticoagulant (assessed by dilute Russell viper venom time) was associated with a significantly increased risk of clinically significant PTS. 174 As a result of the paucity of studies in this area, it is not possible to make specific recommendations on the prevention or treatment of pediatric PTS. Please refer to the Importance of Primary and Secondary Prevention of DVT to Prevent PTS and the Optimizing Anticoagulation Delivery to Prevent PTS sections for general approaches to preventing PTS.
Summary
PTS is a frequent, chronic, burdensome, and costly complication of DVT. This scientific statement has evaluated the body of literature on the pathophysiology, epidemiology, prevention, diagnosis, and treatment of PTS to make evidence-based recommendations to guide clinicians and other healthcare professionals. It is acknowledged that the body of evidence to guide management of PTS is incomplete and that therefore many recommendations rely on lower levels of evidence.
Research Needs
The results of the ATTRACT study on the role of CDT and PCDT in preventing PTS after acute proximal DVT 108 are eagerly awaited. There is also a pressing need for research on the following aspects of PTS: 
Pathophysiology and Risk Factors
